Result Page 10 for Carl icahn news & latest pictures from ibtimes.com

People walk past a giant lion sculpture at the MGM Grand Macau hotel resort in Macau

MGM averts bankruptcy, gets $500 million finance bail out

The new structure gives debt-holders a stake and JP Morgan arranges $500 million

Stocks boosted by Chesapeake, financials

The stock market is up slightly as Chesapeake Energy (NYSE:CHK) jumped 8.41 percent and financial stocks rose broadly. However enthusiasm was tempered by the downgrade of American Express (NYSE:AXP).

Chesapeake Energy jumps 7 pct as Carl Icahn increases stake

Chesapeake Energy jumped 6.95 percent at 12:09 p.m. on news that billionaire investor Carl Icahn increased his equity ownership of it from 2.5 percent to more than 5 percent.

Blockbuster plans to close 182 stores by April

Bankrupt video rental chain Blockbuster Inc plans to close 182 stores by the end of the first quarter of next year as it tries to find a way back on its feet.

Insight

More news

More U.S. billionaires pledge to give away wealth

Another 17 U.S. billionaires, including Facebook co-founders Mark Zuckerberg and Dustin Moskovitz, have pledged to give away at least half their fortunes in a philanthropic campaign led by Warren Buffett and Bill Gates.

More billionaires pledge to give away wealth

Motorola sets split-off date on Jan. 4

Motorola, Inc. (MOT) said it has reduced the time frame for its plan to separate handset and cable set-top box businesses Motorola Mobility Holdings, Inc. from the company to January next year.

Dynegy ends Blackstone deal, seeks new bids from potentially interested parties

Energy firm Dynegy Inc said it intends to terminate the merger deal with Blackstone Group and seeks new proposals from potentially interested parties.

Top After-Market NASDAQ Losers (RINO, RNST, ANAD, CHNG, ALTH)

The top after-market NASDAQ stock market losers are: RINO International, Renasant, Anadigics, China Natural Gas, Allos Therapeutics, Sina, Avanir Pharmaceuticals, Mattel, Ariad Pharmaceuticals, and Bob Evans Farms.

Icahn ups Lions Gate bid, values studio at $1 billion

Investor Carl Icahn increased his bid to buy Lions Gate Entertainment Corp on Tuesday to $7.50 per share, valuing the company at $1 billion and sending shares up more than 12 percent.

Analysis: Genzyme shareholders dismiss Sanofi offer

Sanofi-Aventis is doing everything possible to cajole, pressure and manipulate Genzyme Corp into entering acquisition talks based on its opening offer of $69 a share.

Genzyme rejects Sanofi offer as long battle looms

U.S. biotech company Genzyme Inc rejected an $18.5 billion (11.9 billion pound) buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially hostile takeover battle.

Sanofi makes $18.5 billion Genzyme offer public

France's Sanofi-Aventis on Sunday publicly disclosed its $18.5 billion, $69-per-share cash offer for Genzyme Corp in a bid to rouse shareholders after failing to engage the U.S. biotechnology company in merger talks.

Sanofi-Aventis makes $18.5 billion offer for Genzyme

France's Sanofi-Aventis disclosed its $18.5 billion offer for Genzyme Corp in a bid to rouse shareholders after failing to engage the company in merger talks.

Icahn raises stake in Motorola above 10 percent

Billionaire investor Carl Icahn has increased his holding in Motorola Inc to about 10.4 percent, according to documents the company filed with the U.S. Securities and Exchange Commission.

Sanofi investors oppose big hike in Genzyme bid

Sanofi-Aventis investors have urged the drugmaker not to pay more than about $19 billion to land Genzyme, some $10 a share below the price wanted by the U.S. biotech group.

Sanofi owners oppose big hike to $19 billion Genzyme bid

Sanofi-Aventis chief Chris Viehbacher should avoid paying much more than about $70 per share, or a total of $19 billion, to land U.S. biotech group Genzyme, shareholders in the French group say.

James Bond producers worried by indefinite delay

LOS ANGELES - The James Bond 007: Blood Stone video game event in London this month had all the class and splash one would expect from the world's most elegant spy.

Genzyme weighs Sanofi approach: source

Biotechnology company Genzyme Corp is weighing an informal takeover approach from France's Sanofi-Aventis but is not looking to sell the company, a source familiar with the situation said on Monday.

Icahn to sue Lions Gate over note exchange

Billionaire Carl Icahn on Monday accused Lions Gate Entertainment Corp of using scorched-earth tactics to thwart his bid to take over the Hollywood studio and pledged legal action to stop it.

Stock index futures mixed ahead of payrolls

Sstock index futures pointed to a mixed open on Wall Street on Friday, with futures for the S&P 500 down 0.1 percent, Dow Jones futures down 0.12 percent and Nasdaq 100 futures up 0.03 percent at 0745 GMT.

Two IPOs rise, one delayed as U.S. stocks drop

Two initial public offerings rose in their Thursday debuts as the broader U.S. market fell.

Genzyme, Icahn reach accord, ending proxy fight

Activist investor Carl Icahn has abandoned his proxy fight at Genzyme Corp in return for the biotechnology company's acceptance of two of his representatives to its board.

Genzyme and Icahn reach accord

Activist investor Carl Icahn has abandoned his proxy fight at Genzyme Corp in return for the biotechnology company's acceptance of two of his representatives to its board.

Lions Gate, Icahn had talks on takeover bid

Lions Gate Entertainment has spoken to billionaire investor Carl Icahn a couple of times over his hostile $7 per share offer for the company, its chief executive said on Wednesday.

Stock futures point to higher open on Wall Street

Stock index futures pointed to a higher open on Wall Street on Tuesday, with futures for the S&P 500 up 0.5 percent, Dow Jones futures up 0.4 percent and Nasdaq 100 futures up 0.4 percent at 4:10 a.m. EDT.

IBT Spotlight

We Help Businesses Find B2B Service Providers They Can Trust.

Get Listed

CARL ICAHN

Pages